Eris Lifesciences has entered into a strategic alliance with Natco Pharma to commercialise semaglutide in the Indian market, marking a significant move in the country’s diabetes treatment landscape.
Under the partnership, the two companies will collaborate to introduce semaglutide, a GLP-1 receptor agonist widely used in the management of type 2 diabetes, to Indian patients. The alliance brings together Eris Lifesciences’ strong domestic marketing presence and Natco Pharma’s development and manufacturing capabilities.
The launch of semaglutide is expected to expand access to advanced diabetes therapies amid a rising disease burden in India, which is home to one of the largest diabetic populations globally. By leveraging complementary strengths, the companies aim to address growing demand for innovative and effective metabolic care solutions.
The partnership also strengthens Eris Lifesciences’ presence in the anti-diabetes segment, enhancing its cardiometabolic portfolio. For Natco Pharma, the collaboration supports broader commercialisation of its product pipeline in the domestic market.
The move underscores increasing competition and strategic collaborations in India’s diabetes therapy space, as pharmaceutical firms seek to expand offerings in high-growth chronic care segments.
Also Read